Sculier J P
Service de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Bordet, Bruxelles.
Rev Med Brux. 1995 Mar-Apr;16(2):55-63.
Recent progress has, as practical consequence, placed chemotherapy as the first-line therapy for any type of lung cancer, except for stages I and II non-small cell lung cancers where surgery alone remains the best approach so far. Indeed, the introduction of cisplatin-based chemotherapy in front-line ("neo-adjuvant") has significantly improved in non small lung cancer the results of surgery and radiotherapy in stage III and of supportive care in stage IV, mainly in term of survival. The development of new cytostatic agents and growth factors and the evolution of therapeutic concepts have lead to multiple clinical investigations that are reviewed in both small cell and non small cell lung cancers.
实际上，近期的进展已使化疗成为除I期和II期非小细胞肺癌（目前手术仍是其最佳治疗方法）之外的任何类型肺癌的一线治疗方法。确实，一线（“新辅助”）使用以顺铂为基础的化疗已显著改善了非小细胞肺癌III期手术和放疗以及IV期支持治疗的效果，主要体现在生存率方面。新型细胞抑制剂和生长因子的研发以及治疗理念的演变引发了多项临床研究，本文将对小细胞肺癌和非小细胞肺癌的相关研究进行综述。
